202 related articles for article (PubMed ID: 38169778)
1. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.
Wu XK; Yang LF; Chen YF; Chen ZW; Lu H; Shen XY; Chi MH; Wang L; Zhang H; Chen JF; Huang JY; Zeng YY; Yan ML; Zhang ZB
EClinicalMedicine; 2024 Jan; 67():102367. PubMed ID: 38169778
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.
Wu JY; Yin ZY; Bai YN; Chen YF; Zhou SQ; Wang SJ; Zhou JY; Li YN; Qiu FN; Li B; Yan ML
J Hepatocell Carcinoma; 2021; 8():1233-1240. PubMed ID: 34676181
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
Wu SJ; Ruan DD; Wu QY; Tang Y; Zhang JH; Cai SL; Zhou YF; Luo JW; Fang ZT
J Hepatocell Carcinoma; 2023; 10():807-820. PubMed ID: 37292114
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World.
Li X; Fu Z; Chen X; Cao K; Zhong J; Liu L; Ding N; Zhang X; Zhai J; Qu Z
Front Oncol; 2022; 12():950266. PubMed ID: 35860582
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study.
Huang J; Wang ZG; Tao QF; Yang Y; Yuan SX; Gu FM; Liu H; Pan ZY; Jiang BG; Lau WY; Zhou WP
Front Immunol; 2023; 14():1198562. PubMed ID: 37483609
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study.
Sun B; Zhang L; Sun T; Ren Y; Cao Y; Zhang W; Zhu L; Guo Y; Gui Y; Liu F; Chen L; Xiong F; Zheng C
Front Oncol; 2022; 12():982948. PubMed ID: 36172158
[TBL] [Abstract][Full Text] [Related]
8. A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.
Kudo M; Ueshima K; Saeki I; Ishikawa T; Inaba Y; Morimoto N; Aikata H; Tanabe N; Wada Y; Kondo Y; Tsuda M; Nakao K; Ito T; Hosaka T; Kawamura Y; Kuzuya T; Nojiri S; Ogawa C; Koga H; Hino K; Ikeda M; Moriguchi M; Hisai T; Yoshimura K; Furuse J; Arai Y
Liver Cancer; 2024 Feb; 13(1):99-112. PubMed ID: 38344448
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.
Liu QQ; Wang XX; Ji H; Dou QY; Zhang HM
Med Oncol; 2024 Mar; 41(5):91. PubMed ID: 38526607
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience.
Pan X; Wu SJ; Tang Y; Zhou YF; Luo JW; Fang ZT
J Hepatocell Carcinoma; 2023; 10():883-892. PubMed ID: 37324411
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study.
Wu JY; Zhang ZB; Zhou JY; Ke JP; Bai YN; Chen YF; Wu JY; Zhou SQ; Wang SJ; Zeng ZX; Li YN; Qiu FN; Li B; Yan ML
Liver Cancer; 2023 Aug; 12(3):229-237. PubMed ID: 37767067
[TBL] [Abstract][Full Text] [Related]
13. Transcatheter arterial chemoembolisation combined with lenvatinib and cabozantinib in the treatment of advanced hepatocellular carcinoma.
Liu H; Gan XM; Sun JM; Yang Q; Zhang DZ; Zuo YQ; Liu FL; Li B; Tan QL; Zhang J
Int Immunopharmacol; 2024 Mar; 130():111510. PubMed ID: 38422766
[TBL] [Abstract][Full Text] [Related]
14. A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma.
Teng Y; Ding X; Li W; Sun W; Chen J
Technol Cancer Res Treat; 2022; 21():15330338221075174. PubMed ID: 35313780
[No Abstract] [Full Text] [Related]
15. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma: A single-center, prospective, single-arm clinical trial.
Ren Y; Li Y; Cao M; Tang Y; Yuan F; Yang G; He Z; Shi Z; Su X; Yao Z; Deng M
Chin J Cancer Res; 2024 Apr; 36(2):114-123. PubMed ID: 38751440
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of lenvatinib-transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective study.
Oshita K; Kobayashi T; Namba Y; Fukuhara S; Matsubara K; Takei D; Nakano R; Okamoto W; Sakai H; Tanimine N; Nakahara T; Kuroda S; Tahara H; Ohira M; Kawaoka T; Ide K; Imamura M; Aikata H; Ohdan H
BMJ Open; 2023 Oct; 13(10):e073797. PubMed ID: 37798025
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective Study.
Wu JY; Wu JY; Fu YK; Ou XY; Li SQ; Zhang ZB; Zhou JY; Li B; Wang SJ; Chen YF; Yan ML
Ann Surg Oncol; 2024 May; 31(5):3073-3083. PubMed ID: 38316732
[TBL] [Abstract][Full Text] [Related]
20. Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study.
Duan X; Li H; Kuang D; Chen P; Zhang K; Li Y; He X; Xing C; Wang H; Liu Y; Xie L; Zhang S; Zhang Q; Zhu P; Dong H; Xie J; Li H; Wang Y; Shi M; Jiang G; Xu Y; Zhou S; Shang C; Ren J; Han X
Hepatol Int; 2023 Aug; 17(4):915-926. PubMed ID: 37012542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
